With mutant enrichment technologies, Insight™ Onco is able to detect cancer related mutations at minimum frequencies of 0.05%. With high-level sensitivity, the system can detect DNA mutation present in cancer, using not only a small quantity of tissues, but also blood plasma and urine. As its analysis can be performed with a small quantity of blood or urine alone, it can conduct safer and regular gene mutation monitoring than existing sampling methods. Moreover, as Insights™ Onco can perform multiple analysis based on Next Generation Sequencing (NGS), single sampling can simultaneously detect several instances of mutation present in cancer-related genes such as EGFR, BRAF, KRAS, PIK3CA, and HER2. As it can prescribe a target drug for cancer patients with certain DNA abnormality, the analysis can improve the treatment efficiency and minimize side effects.